Neel Parekh, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,888 of the $133,366 with a category attached, or 70.4%. Antares Pharma, Inc. accounts for 77.4% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $49,871 and has fallen 66.1% since, to $16,927 in 2025. Among urology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $244.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Antares Pharma, Inc.$103K
- Boston Scientific$20K
- Coloplast$3K
- Olympus America Inc.$1K
- Procept Biorobotics Corporation$654
- Endo Pharmaceuticals Inc.$544
- plus $4K from 24 others
What the payments were for
- Consulting fees$6,6355%
- Speaking & faculty fees$93,88870%
- Travel & lodging$12,2949%
- Food & beverage$20,45315%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Antares Pharma, Inc. | 106 | $103,226 |
| Boston Scientific | 283 | $20,379 |
| Coloplast | 33 | $2,980 |
| Olympus America Inc. | 21 | $1,427 |
| Procept Biorobotics Corporation | 6 | $654 |
| Endo Pharmaceuticals Inc. | 25 | $544 |
| Biotissue Holdings Inc. | 6 | $519 |
| Astellas Pharma US Inc | 6 | $396 |
| Teleflex LLC | 4 | $394 |
| Sumitomo Pharma America, Inc. | 8 | $289 |
| Neotract Inc. | 3 | $250 |
| EDAP Technomed Inc | 1 | $248 |
| Tolmar, Inc. | 11 | $241 |
| Halozyme Inc | 5 | $220 |
| Aroa Biosurgery Incorporated | 2 | $189 |
| Endo USA, Inc. | 6 | $187 |
| Urogen Pharma, Inc. | 5 | $179 |
| Calyxo, Inc. | 3 | $174 |
| Dornier Medtech America, Inc | 1 | $157 |
| Kerecis Limited | 1 | $124 |
| Myovant Sciences Inc. | 1 | $119 |
| Bard Access Systems, Inc. | 1 | $100 |
| Cook Medical LLC | 1 | $96 |
| Photocure Inc | 1 | $65 |
| Caldera Medical, Inc | 1 | $65 |
| Progenics Pharmaceuticals, Inc. | 1 | $64 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $30 |
| Pharmaand GmbH | 1 | $22 |
| Johnson & Johnson | 1 | $14 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYOSTED$82,020
- TLANDO$62,989
- AMS 800 Artificial Urinary Sphincter$5,705
- AMS$2,208
- TITAN$1,886
- AMS 700$1,311
- iTIND System$1,067
- GENERAL - THERAPIES$1,000
- AMS 700 CXR RTE KIT$984
- GENERAL ERECTILE DYSFUNCTION$573
- Kerecis SurgiClose$496
- AquaBeam Robotic System$361
- XIAFLEX$354
- NOCDURNA$344
- REZUM$249
- UroLift$247
- AQUABEAM SYSTEM$239
- NEOX$235
- CLARIX$235
- XTANDI$225
How this compares
$133,366 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 62 | $54,624 |
| Testosterone | 42 | $16,794 |
| GemtesaVibegron | 17 | $10,085 |
| Tadalafil | 22 | $4,244 |
| Potassium Citrate ErPotassium Citrate | 29 | $4,089 |
| Tamsulosin Hcl | 213 | $3,506 |
| Finasteride | 217 | $3,307 |
| Testosterone Cypionate | 53 | $2,776 |
| Dutasteride | 24 | $1,977 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 45 | $972 |
| Amitriptyline Hcl | 22 | $430 |
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $332 |
| Cefdinir | 24 | $249 |
| Doxazosin Mesylate | 11 | $232 |
| Oxybutynin Chloride | 11 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $396 | $54,62462 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $289 | $10,08517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.
Other urology in Akron
- David DrevnaAkron$15K
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
- Sandip VasavadaCleveland$263K
- Jihad KaoukCleveland$234K
- Benjamin MartinGahanna$205K
- Ruben OlivaresCleveland$184K
- Abhinav SidanaCincinnati$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.